Key Points
- CEO Chandler Robinson sold 29,056 Monopar Therapeutics shares at an average price of $88, generating approximately $2.56 million. The Rule 10b5-1 transaction reduced his ownership by 22.64%, leaving him with 99,267 shares.
- MNPR opened at $83.72, with a market capitalization of about $561.8 million and a 12-month trading range of $50.07 to $124.82. The company remains unprofitable, though its latest quarterly loss of $0.62 per share was slightly better than analyst expectations.
- Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $121.36, despite one sell rating and one hold rating.
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) CEO Chandler Robinson sold 29,056 shares of the company's stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $88.00, for a total transaction of $2,556,928.00. Following the completion of the transaction, the chief executive officer owned 99,267 shares in the company, valued at approximately $8,735,496. This trade represents a 22.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Monopar Therapeutics Price Performance
Monopar Therapeutics stock opened at $83.72 on Tuesday. The firm's 50-day moving average is $109.77 and its two-hundred day moving average is $82.32. The stock has a market capitalization of $561.76 million, a P/E ratio of -38.58 and a beta of 1.49. Monopar Therapeutics Inc. has a 12-month low of $50.07 and a 12-month high of $124.82.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.02. As a group, analysts forecast that Monopar Therapeutics Inc. will post -2.98 EPS for the current year.
Institutional Investors Weigh In On Monopar Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp purchased a new position in shares of Monopar Therapeutics in the 2nd quarter worth about $7,124,000. Walleye Capital LLC purchased a new stake in shares of Monopar Therapeutics during the 1st quarter worth about $3,458,000. Siren L.L.C. grew its holdings in shares of Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company's stock worth $14,800,000 after purchasing an additional 57,820 shares during the period. Bank of America Corp DE increased its position in Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company's stock worth $3,271,000 after purchasing an additional 53,336 shares in the last quarter. Finally, ADAR1 Capital Management LLC increased its position in Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts recently commented on MNPR shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Zacks Research cut Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 13th. Barclays reaffirmed an "overweight" rating and set a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. BTIG Research increased their price objective on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Finally, UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $121.36.
View Our Latest Stock Report on Monopar Therapeutics
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company's programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.
Monopar's lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
